Policy | October 12, 2025
AstraZeneca to lower cost of medicines for American patients
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
